Get Legal Help

NuvaRing

NuvaRing is a low-estrogen contraceptive device approved by the FDA in October 2001. NuvaRing is a soft, flexible, two-inch vaginal ring that is worn for three weeks and removed for one week. A combination hormonal contraceptive, NuvaRing combines ethinyl estradiol (the estrogen hormone component) and etonogestrel (the progestin hormone component). Over a three week period the device releases .015 mg ethinyl estradiol and .120 mg etonogestrel per day into the user’s body.

Side Effects Associated with NuvaRing

  • Blood Clots 
  • Strokes 
  • Heart Attacks 
  • Myocardial Infarction 
  • Pulmonary Embolism 

Note - Do not change medications without first consulting your doctor.

This is a website of Sokolove Law, LLC and is not affiliated with or sponsored by the manufacturers of NuvaRing. NuvaRing is a registered trademark of N.V. Organon (Netherlands).

Please fill out the form below to contact a Case Manager.